Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Invested Capital (2016 - 2025)

Historic Invested Capital for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$99.0 million.

  • Northwest Biotherapeutics' Invested Capital fell 3956.21% to -$99.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.0 million, marking a year-over-year decrease of 3956.21%. This contributed to the annual value of -$84.9 million for FY2024, which is 5005.57% down from last year.
  • Northwest Biotherapeutics' Invested Capital amounted to -$99.0 million in Q3 2025, which was down 3956.21% from -$91.3 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Invested Capital peaked at -$11.3 million during Q1 2021, and registered a low of -$1.3 billion during Q3 2023.
  • For the 5-year period, Northwest Biotherapeutics' Invested Capital averaged around -$118.8 million, with its median value being -$52.3 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 369790.34% in 2023, then surged by 9469.47% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Invested Capital stood at -$17.2 million in 2021, then tumbled by 176.31% to -$47.5 million in 2022, then dropped by 19.02% to -$56.6 million in 2023, then tumbled by 50.06% to -$84.9 million in 2024, then fell by 16.58% to -$99.0 million in 2025.
  • Its Invested Capital stands at -$99.0 million for Q3 2025, versus -$91.3 million for Q2 2025 and -$90.0 million for Q1 2025.